A wet gloomy day in San Francisco was brightened up by some small biotech talks
San Francisco – The other day I mentioned that we could expect some cross pollination across several recent conferences and this latest post on Kura Oncology is one such example of that genre.
We’ve been following their story longitudinally for a while now and with a lot suddenly going on, 2020 could well turn out to be an crucial year for the company.
There is no doubt they have been pursuing a very focused precision medicine approach with tipifarnib and executing nicely on that strategy so far, but as more indications and additional pipeline agents move into the clinic do the same principles still apply?
To find out, we interviewed a couple of their senior executives and discussed both current progress as well as where they are headed…
To learn more from our oncology coverage and get a heads up on our latest commentary from the JPM and ASH annual meetings, subscribers can log-in or you can click to gain access to BSB Premium Content.
Cancer cells Source: Dr. Cecil Fox, NCI
As part of our ongoing mini-series on small emerging companies to watch out for, we have two quite different biotechs focusing on different aspects of immunotherapy on deck today.
We look at what we know, what we recently learned and where things are likely headed in the near to medium term future.
As always, there’s good and bad news along the way, so what are the pitfalls and what’s to be cheerful or encouraged about?
To learn more and get a heads up on our latest immunotherapy coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.